Q4-FY26 · Omar Gora
My immediate priority over the next few months will be to spend time with our teams, customers and sites. By the end of this fiscal year, the intent is to create a strategic blueprint for growth and sustainable value creation.
Cohance Lifesciences · tone and specificity signals across the available quarters.
Language signals
My immediate priority over the next few months will be to spend time with our teams, customers and sites. By the end of this fiscal year, the intent is to create a strategic blueprint for growth and sustainable value creation.
We believe the business is moving towards a bottoming out phase with quarter 1 FY27 to be the low point.
The challenges during FY26 were concentrated around a limited set of products and customer specific situations rather than reflecting any structural weakness in the portfolio.